Business Development

Business Development

The Solution to Oral Peptide Delivery
Unigene’s Industry Leading Oral Peptide Delivery Platform

Unigene is dedicated to developing long-term co-development and licensing partnerships using our Peptelligence™ technology platform and related intellectual property and know-how to formulate, test and commercialize orally delivered therapeutic peptides. Over the past two years, Unigene has demonstrated a successful track record for applying our clinically validated oral peptide drug delivery technology to our partners’ proprietary peptide programs. Unigene has established the expertise and capabilities necessary to perform pre-clinical studies, formulation and analytical development, GMP manufacturing of tablets for clinical trials, and regulatory expertise and documentation, to reduce risk, cost and time to market of our partners’ programs.

• Peptelligence™ Offers:
• Patient friendly oral tablet dosing
• Increased commercial viability
• Greater market potential
• Lifecycle management
• Patent protection until 2030

For information on how Unigene can orally deliver your peptide please contact:
Business Development
businessdevelopment@unigene.com

Peptelligence Portfolio